Diagnosis of pancreatic cancer using serum proteomic profiling

被引:77
作者
Bhattacharyya, S
Siegel, ER
Petersen, GM
Chari, ST
Suva, LJ
Haun, RS
机构
[1] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Dept Orthopaed Surg, Ctr Orthopaed Res, Little Rock, AR 72205 USA
[3] Univ Arkansas Med Sci, Dept Biometry, Little Rock, AR 72205 USA
[4] Mayo Clin, Div Epidemiol, Rochester, MN USA
[5] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA
来源
NEOPLASIA | 2004年 / 6卷 / 05期
关键词
SELDI; surface-enhanced laser desorption/ionization; mass spectrometry; proteomics; early detection;
D O I
10.1593/neo.04262
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the United States, mortality rates from pancreatic cancer (PCa) have not changed significantly over the past 50 years. This is due, in part, to the lack of early detection methods for this particularly aggressive form of cancer. The objective of this study was to use high-throughput protein profiling technology to identify biomarkers in the serum proteome for the early detection of resectable PCa. Using surface-enhanced laser desorption/ionization mass spectrometry, protein profiles were generated from sera of 49 PCa patients and 54 unaffected individuals after fractionation on an anion exchange resin. The samples were randomly divided into a training set (69 samples) and test set (34 samples), and two multivariate analysis procedures, classification and regression tree and logistic regression, were used to develop classification models from these spectral data that could distinguish PCa from control serum samples. In the test set, both models correctly classified all of the PCa patient serum samples (100% sensitivity). Using the decision tree algorithm, a specificity of 93.5% was obtained, whereas the logistic regression model produced a specificity of 100%. These results suggest that high-throughput proteomics profiling has the capacity to provide new biomarkers for the early detection and diagnosis of PCa.
引用
收藏
页码:674 / 686
页数:13
相关论文
共 35 条
[21]  
PIETRI F, 1991, BRIT J IND MED, V48, P583
[22]   Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes [J].
Poon, TCW ;
Yip, TT ;
Chan, ATC ;
Yip, C ;
Yip, V ;
Mok, TSK ;
Lee, CCY ;
Leung, TWT ;
Ho, SKW ;
Johnson, PJ .
CLINICAL CHEMISTRY, 2003, 49 (05) :752-760
[23]   THE USE OF SEROLOGIC TUMOR-MARKERS IN GASTROINTESTINAL MALIGNANCIES [J].
POSNER, MR ;
MAYER, RJ .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1994, 8 (03) :533-553
[24]  
Rai AJ, 2002, ARCH PATHOL LAB MED, V126, P1518
[25]  
Rosewicz S, 1997, LANCET, V349, P485
[26]   Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective [J].
Sakorafas, GH ;
Tsiotou, AG ;
Tsiotos, GG .
CANCER TREATMENT REVIEWS, 2000, 26 (01) :29-52
[27]   COMPARISON OF CA19-9 WITH OTHER TUMOR-MARKERS IN THE DIAGNOSIS OF CANCER OF THE PANCREAS [J].
SATAKE, K ;
TAKEUCHI, T .
PANCREAS, 1994, 9 (06) :720-724
[28]   CA19-9 AS A SCREENING AND DIAGNOSTIC-TOOL IN SYMPTOMATIC PATIENTS - THE JAPANESE EXPERIENCE [J].
SATAKE, K ;
TAKEUCHI, T ;
HOMMA, T ;
OZAKI, H .
PANCREAS, 1994, 9 (06) :703-706
[29]  
Srinivas PR, 2001, CLIN CHEM, V47, P1901
[30]  
STEINBERG W, 1990, AM J GASTROENTEROL, V85, P350